Cooper Companies Posts Strong Q2, Net Income Jumps 37%
Ticker: COO · Form: 10-Q · Filed: May 30, 2025 · CIK: 711404
Sentiment: bullish
Topics: Ophthalmic Goods, Medical Devices, Women's Healthcare, Earnings Growth, Contact Lenses, Healthcare Sector, Q2 2025
Related Tickers: COO, JNJ, BLCO
TL;DR
COO's Q2 numbers are solid, showing strong growth in both revenue and net income, making it a buy for long-term healthcare investors.
AI Summary
COOPER COMPANIES, INC. reported strong financial performance for the six months ended April 30, 2025, with revenue reaching $1.86 billion, an increase from $1.74 billion in the prior year period. Net income attributable to Cooper Companies, Inc. shareholders for the six months ended April 30, 2025, was $261.2 million, a significant improvement from $190.4 million in the same period last year. The company's CooperVision segment saw robust growth, driven by increased demand for daily disposable contact lenses. Key business changes include continued investment in research and development, particularly in new product introductions within the CooperVision and CooperSurgical segments. Risks highlighted include foreign currency fluctuations, which impacted revenue by $10.3 million for the three months ended April 30, 2025, and potential supply chain disruptions. The strategic outlook emphasizes expanding market share in specialty contact lenses and fertility solutions, leveraging its diversified portfolio to drive future profitability.
Why It Matters
This strong performance by Cooper Companies, Inc. signals robust demand in the ophthalmic and women's healthcare markets, which is positive for investors seeking growth in defensive healthcare sectors. Employees benefit from a stable and expanding company, potentially leading to increased job security and opportunities. Customers gain from continued innovation in contact lenses and medical devices, improving quality of life. In a competitive landscape, Cooper's ability to increase net income by 37% demonstrates its effective strategy against rivals like Johnson & Johnson Vision and Bausch + Lomb, solidifying its market position.
Risk Assessment
Risk Level: medium — The company faces medium risk due to exposure to foreign currency fluctuations, which negatively impacted revenue by $10.3 million for the three months ended April 30, 2025. Additionally, the filing mentions potential supply chain disruptions, which could affect product availability and profitability, though specific financial impacts are not quantified.
Analyst Insight
Investors should consider adding COO to their portfolios, given the strong revenue growth to $1.86 billion and a 37% increase in net income to $261.2 million. The company's focus on specialty contact lenses and fertility solutions positions it well for continued market expansion and sustained profitability.
Financial Highlights
- revenue
- $1.86B
- net Income
- $261.2M
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| CooperVision | $1.86B |
Key Numbers
- $1.86B — Revenue (Increased from $1.74B in the prior year period for the six months ended April 30, 2025.)
- $261.2M — Net Income (Increased from $190.4M in the prior year period for the six months ended April 30, 2025, representing a 37% jump.)
- 37% — Net Income Growth (Percentage increase in net income attributable to shareholders for the six months ended April 30, 2025, compared to the prior year.)
- $10.3M — Foreign Currency Impact (Negative impact on revenue for the three months ended April 30, 2025.)
Key Players & Entities
- COOPER COMPANIES, INC. (company) — filer of the 10-Q
- CooperVision (company) — segment of Cooper Companies, Inc. experiencing robust growth
- CooperSurgical (company) — segment of Cooper Companies, Inc. with new product introductions
- Johnson & Johnson Vision (company) — competitor in the ophthalmic market
- Bausch + Lomb (company) — competitor in the ophthalmic market
- $1.86 billion (dollar_amount) — total revenue for the six months ended April 30, 2025
- $1.74 billion (dollar_amount) — total revenue for the six months ended April 30, 2024
- $261.2 million (dollar_amount) — net income attributable to Cooper Companies, Inc. shareholders for the six months ended April 30, 2025
- $190.4 million (dollar_amount) — net income attributable to Cooper Companies, Inc. shareholders for the six months ended April 30, 2024
- $10.3 million (dollar_amount) — negative impact of foreign currency fluctuations on revenue for the three months ended April 30, 2025
FAQ
What were Cooper Companies' revenues for the six months ended April 30, 2025?
Cooper Companies, Inc. reported revenues of $1.86 billion for the six months ended April 30, 2025, an increase from $1.74 billion in the same period of the prior year.
How did Cooper Companies' net income change in Q2 2025?
Net income attributable to Cooper Companies, Inc. shareholders for the six months ended April 30, 2025, was $261.2 million, a significant increase from $190.4 million in the comparable prior year period.
What segments contributed to Cooper Companies' growth?
The CooperVision segment showed robust growth, driven by increased demand for daily disposable contact lenses. The CooperSurgical segment also contributed through new product introductions.
What are the main risks identified in Cooper Companies' 10-Q filing?
Key risks include foreign currency fluctuations, which negatively impacted revenue by $10.3 million for the three months ended April 30, 2025, and potential supply chain disruptions.
What is Cooper Companies' strategic outlook?
The strategic outlook for Cooper Companies, Inc. focuses on expanding market share in specialty contact lenses and fertility solutions, leveraging its diversified portfolio to drive future profitability.
How did foreign currency impact Cooper Companies' revenue?
Foreign currency fluctuations had a negative impact of $10.3 million on Cooper Companies' revenue for the three months ended April 30, 2025.
What should investors consider regarding Cooper Companies' performance?
Investors should note the strong revenue growth to $1.86 billion and the 37% increase in net income to $261.2 million, indicating solid operational performance and market demand for its products.
What type of products does Cooper Companies specialize in?
Cooper Companies specializes in ophthalmic goods, primarily contact lenses through its CooperVision segment, and women's healthcare products and medical devices through its CooperSurgical segment.
When was Cooper Companies' 10-Q filed?
The 10-Q for Cooper Companies, Inc. was filed on May 30, 2025, covering the period ended April 30, 2025.
Did Cooper Companies mention any new product introductions?
Yes, the filing mentions continued investment in research and development, particularly in new product introductions within both the CooperVision and CooperSurgical segments.
Risk Factors
- Foreign Currency Fluctuations [medium — financial]: The company experienced a negative impact of $10.3 million on revenue for the three months ended April 30, 2025, due to foreign currency fluctuations. This highlights the sensitivity of its international sales to exchange rate movements.
- Supply Chain Disruptions [medium — operational]: Potential supply chain disruptions remain a risk for the company. While specific impacts are not detailed in the summary, such disruptions could affect product availability and delivery timelines.
Industry Context
The ophthalmic goods industry, where Cooper Companies operates, is characterized by continuous innovation in contact lens technology and a growing demand for vision correction solutions. Key trends include the increasing adoption of daily disposable lenses and advancements in surgical and diagnostic tools for eye care.
Regulatory Implications
As a medical device and healthcare company, Cooper Companies is subject to stringent regulatory oversight from bodies like the FDA. Compliance with evolving regulations regarding product safety, manufacturing standards, and marketing practices is crucial for continued market access and growth.
What Investors Should Do
- Monitor foreign currency impact
- Assess R&D investment returns
- Evaluate supply chain resilience
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the 10-Q filing for Cooper Companies, Inc., providing the latest financial and operational details.)
- Fiscal Year End
- The last day of a company's accounting year. (Cooper Companies, Inc. has a fiscal year end of October 31st, meaning the reported period (ending April 30, 2025) falls within its 2025 fiscal year.)
Year-Over-Year Comparison
The current six-month period shows a significant increase in net income to $261.2 million from $190.4 million in the prior year, representing a 37% jump. Revenue also saw an increase to $1.86 billion from $1.74 billion in the prior year period. No new major risks were introduced, but existing risks like foreign currency fluctuations and supply chain disruptions continue to be relevant.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 30, 2025 regarding COOPER COMPANIES, INC. (COO).